US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Interim report January-March 2014: Strengthened operating margin

    First quarter in brief:· Sales growth was 12 percent in local currency. Sales amounted to SEK 119 (105) million, corresponding to an increase of 14 percent in SEK. · Operating income (EBIT) amounted to SEK 30 (17) million, corresponding to an operating margin of 25 (16) percent. Operating income included a recovered additional purchase price of SEK 2 million regarding the acquisition of Cryo Management Ltd. Adjusted for this, the operating margin amounted to 23 (16) percent. · Net income amounted to SEK 22 (12) million, which gave earnings per share of SEK 1.12 (0.60). Gothenburg,

    Interim report January-March 2013: High growth and increased income

    First quarter Continuing operations: · Sales growth was 27 percent in local currency. Sales amounted to SEK 105 (86) million, corresponding to an increase of 22 percent in SEK. · Operating income (EBIT) amounted to SEK 17 (10) million, corresponding to an operating margin of 16 (12) percent. · Net income amounted to SEK 12 (7) million, which gave earnings per share of SEK 0.61 (0.38). After the end of the period · During 2010 Vitrolife entered into a collaboration agreement with the Danish company HertArt ApS with a view to developing a new range of disposable plastic

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - March 2013. The presentation will be held in English.Time: Friday, April 19, 2013 at 10 a.m. CET. Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=187229 or shortly before the conference starts on: Sweden dial in number: +46 (0)8 5052 0110 UK dial in number: +44 (0)20 7162 0077 Conference name: Vitrolife, conference ID: 931066 Vitrolife participants:Thomas

    Annual report 2012

    Today Vitrolife is publishing the Annual Report for 2012 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com.The printed version of the Annual Report will be distributed by mail during the week commencing 15 April. It will be distributed to Nordic shareholders who are new from last year and to remaining shareholders who have requested that the annual report should be sent to them. The printed version of the Annual Report can be ordered on the company's website www.vitrolife.com, by phone +46 (0)31 721 80 00 or by email info@

    Report on operations 2012

    High growth and improved operating marginFourth quarter Continuing operations: · Sales growth was 24 percent in local currency. Sales amounted to SEK 98 (82) million, corresponding to an increase of 20 percent in SEK. · Operating income (EBIT) amounted to SEK 12 (2) million, corresponding to an operating margin of 12 (2) percent. · On October 1 the transplantation business was distributed to the shareholders of Vitrolife, and it is thus reported in this interim report as discontinued operations. The distribution entailed a non-taxable financial capital gain of SEK 303 million

    Conference call on the Report on Operations 2012

    Invitation to attend Vitrolife’s conference call regarding presentation of the Report on Operations 2012. The presentation will be held in English.Time: Thursday, February 7, 2012 at 10.00 a.m. CET. Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=186676 or shortly before time of the conference starts on: Sweden dial in number: +46 (0)8 5052 0110 UK dial in number: +44 (0)20 7162 0077 Conference name: Vitrolife, conference ID: 928446 Vitrolife participants:Thomas Axelsson,

    Vitrolife’s share capital and number of shares on November 30, 2012

    As per November 30, 2012, the total number of shares in Vitrolife AB (publ) amounts to 19,830,936, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 20,227,554.74.At the beginning of the month the total number of shares in the company amounted to 19,562,769, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 19,954,024.38 The increase in the number of shares by 268.167 during the month of November is due to the private placement that was directed to the previous owners of Cryo Management Ltd to partly finance the acquisition of Cryo

    Private placement regarding Cryo Management fully subscribed

    The Extraordinary General Meeting of Vitrolife held on September 24 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the acquisition of Cryo Management Ltd. In accordance with the resolution, the board of directors of Vitrolife has resolved to determine that the company’s share capital shall be increased with not more than SEK 273.530,34 by an issue of not more than 268,167 shares. The new share issue was fully subscribed.The Extraordinary General Meeting of Vitrolife held September 24 adopted a resolution regarding a private placement of EUR 1.

    Vitrolife completes acquisition of Cryo Management Ltd

    On June 29 Vitrolife announced that the company had entered into an agreement to acquire 100% ownership in Cryo Management Ltd. Vitrolife has now completed the transaction and Cryo Management Ltd is now a part of Vitrolife.Cryo Management Ltd is one of the world’s leading players within time-lapse for IVF, developer of Primo Vision time-lapse embryo monitoring system. The company has approximately 20 employees and is based in Hungary. The acquisition was completed under essentially the same conditions as were communicated on June 29. “We are pleased to be able to welcome our new

    Vitrolife acquires Cryo Management Ltd and thereby broadens the product portfolio

    Vitrolife has entered into an agreement to acquire Cryo Management Ltd, one of the world’s leading players within time-lapse for IVF, developer of Primo Vision time-lapse embryo monitoring system. Through the acquisition Vitrolife gains access to a product portfolio in the form of successful time-lapse products for IVF and increased knowledge within IVF technology and embryo development.Vitrolife has entered into an agreement to acquire 100% ownership in Cryo Management Ltd by September for a purchase sum of EUR 5 million, which can be increased to EUR 9 million upon the fulfilment of

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe